CYT 538
Alternative Names: CYT-538Latest Information Update: 11 Nov 2022
At a glance
- Originator Cytovia Therapeutics
- Class Antineoplastics; CAR-NK cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; Natural killer cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Multiple myeloma
- Discontinued Lymphoma
Most Recent Events
- 11 Nov 2022 Cytovia Therapeutics plans to submit IND application to US FDA for Multiple myeloma in 2025 (Cytovia Therapeutics pipeline, November 2022)
- 18 Apr 2022 Discontinued for Lymphoma in USA (Parenteral) (Cytovia Therapeutics pipeline, April 2022)
- 18 Apr 2022 Preclinical trials in Multiple myeloma in USA (Parenteral) (Cytovia Therapeutics pipeline, April 2022)